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Targeted ablation of the  
vitamin D 1α-hydroxylase gene: 
getting to the heart of the matter
Ravi Thadhani1
Targeted gene ablation technology has uncovered biological 
mechanisms that have led to important therapeutics in humans. 
In a study by Zhou et al., ablation of the 1α-hydroxylase gene led 
to hypertension, cardiac hypertrophy, and systolic dysfunction, 
and this cardiac phenotype was rescued with exogenous 1,25-
dihydroxyvitamin D administration.
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In 2007 the Nobel Committee honored 
Evans, Capecchi, and Smithies for their 
seminal contributions that led to the 
development of specific gene knockout 
(KO) mouse models.1–3 This truly amaz-
ing technology has allowed countless 
investigators in all disciplines of medi-
cine to manipulate their specific gene 
of choice and, by doing so, to uncover 
its biological function by examining 
the downstream consequences. In the 
nephrology community, we have not 
been without benefit, as this technology 
has led to a profound understanding of 
various diseases, including nephrotic 
syndrome,4 renal tubular acidosis,5 and 
polycystic kidney disease,6 to name a few. 
In this process, novel therapeutic options 
have been uncovered.7 Gene-targeted 
ablation has also allowed us to appre-
ciate the downstream consequences of 
altered vitamin D metabolism in which 
the kidney plays an intimate role.8,9
Classic experiments performed dur-
ing the 1970s in nephrectomized ani-
mals demonstrated that the kidney 
is the primary organ responsible for 
converting the circulating form of 
vitamin D, 25-hydroxyvitamin D 
(25(OH)D3), to the hormonal form of 
vitamin D, 1,25-dihydroxyvitamin D 
(1,25(OH)2D3), a process that is tightly 
regulated.10 The renal mitochondrial 
1α-hydroxylase (CYP27B1) enzyme 
was cloned and extensively studied as 
a primary cause of inherited rickets.11 
Subsequently, autocrine production of 
1,25(OH)2D3 was documented in sev-
eral other cell types, including skin, brain, 
placenta, and circulating cells such as 
macrophages, all of which were subse-
quently found to express 1α-hydroxylase 
activity.11 This enzyme was successfully 
knocked out by Goltzman and others,8 
and the downstream consequences 
— focusing on mineral and bone effects 
— included hypocalcemia, hyperparathy-
roidism, and skeletal abnormalities. These 
in vivo alterations mimic those classically 
described in patients with chronic renal 
failure.11 The renal enzyme is primarily 
expressed in the proximal tubule and is 
regulated by 1,25(OH)2D3, phosphorus, 
and parathyroid hormone, the first two 
inhibiting its activity and the third stimu-
lating its activity.12 Recently, regulation by 
fibroblast growth factor-23 has also been 
uncovered.11 Although all four appear to 
regulate kidney 1α-hydroxylase activity, 
it is likely that 1α-hydroxylase activity 
outside the kidney is not regulated by all 
of these same factors.
Zhou et al.13 (this issue) have now dem-
onstrated in a series of elegant experi-
ments that a defect in the 1α-hydroxylase 
gene and the lack of 1,25(OH)2D3 in vivo 
lead to the cardiac phenotype of hyper-
tension, left ventricular and cardiomyo-
cyte hypertrophy, and impaired systolic 
function, and that this phenotype was 
not rescued by normalization of ambi-
ent calcium or phosphorus levels but 
was rescued by replacement with the 
hormone 1,25(OH)2D3. Furthermore, 
marked elevation of renal renin and 
angiotensinogen expression and protein 
levels, and corresponding findings in the 
plasma, including plasma aldosterone lev-
els, were also normalized by 1,25(OH)2D3 
administration. Cardiac renin mRNA and 
protein levels were markedly elevated in 
1α-hydroxylase KO compared with wild-
type animals, and both were nearly nor-
malized by 1,25(OH)2D3 administration. 
Real-time polymerase chain reaction with 
reverse transcription demonstrated the 
presence of both the vitamin D receptor 
(VDR) and 1α-hydroxylase in cardiac tis-
sue of wild-type animals, and, as expected, 
only VDR in 1α-hydroxylase KO animals. 
Thus, although local cardiac conversion 
of 25(OH)D3 to 1,25(OH)2D3 may be 
important, the 1α-hydroxylase KO model 
distinctly demonstrated that exogenous 
1,25(OH)2D3 rescued the cardiac phe-
notype in animals without a functional 
1α-hydroxylase enzyme.
Cardiac alterations were also normal-
ized after treatment with an angiotensin-
converting enzyme inhibitor or an 
angiotensin II receptor antagonist, sug-
gesting that the effect of 1,25(OH)2D3 on 
the heart may be mediated through the 
renin–angiotensin system (RAS). In both 
the 1,25(OH)2D3-treated and the RAS 
inhibitor-treated animals, blood pres-
sure was reduced; thus blood pressure 
reduction also may have contributed to 
the observed cardioprotective effects. It 
would have been interesting to exam-
ine 1α-hydroxylase KO animals treated 
with an antihypertensive agent known 
not to affect the RAS to determine 
whether the cardioprotective effects 
were primarily linked to the local RAS. 
In animals treated with RAS inhibitors, 
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however, renal renin expression was 
elevated, whereas animals treated with 
1,25(OH)2D3 demonstrated suppressed 
renal renin expression. Zhou and col-
leagues13 concluded that 1,25(OH)2D3 
regulates cardiac RAS and, via this 
mechanism, confers cardioprotection.
As with all in vivo or clinical observa-
tions, corroborative studies strengthen 
the biological relevance of any finding. 
At least two previously described in vivo 
models of altered vitamin D metabolism 
complement the findings of Zhou et al.13 
First, gene-targeted ablation of the vita-
min D receptor — the VDR KO mouse 
model — demonstrated elevated blood 
pressure, cardiac and cardiomyocyte 
hypertrophy, and increased cardiac renin 
expression.14,15 Second, we recently dem-
onstrated that activated vitamin D sterol 
administered to the Dahl salt-sensitive rat 
significantly attenuated the progression 
of cardiac hypertrophy and improved the 
functional, molecular, biochemical, and 
genetic cardiac parameters otherwise 
altered in this reliable animal model of 
cardiac abnormalities (Figure 1).16 We 
documented that the Dahl salt-sensitive 
rat also becomes profoundly 25(OH)D3 
deficient, which had been reported in 
the past. Cardiac improvements were 
independent of blood pressure, as ther-
apy did not significantly reduce blood 
pressure. Cardiac-specific renin expres-
sion was markedly attenuated with 
vitamin D sterol treatment; this is similar 
to the results published by Zhou et al.13
Thus, multiple lines of evidence sup-
port the concept that 1,25(OH)2D3 has a 
cardiovascular protective effect, and that 
this effect requires ligand-bound VDR 
activation. Whether 1,25(OH)2D3 acts 
directly or indirectly (for example, via 
renal- or vascular-mediated benefits) on 
the heart, or via genomic or nongenomic 
mechanisms, remains unsettled. Future 
efforts, including those examining the 
cardiac effects of 1,25(OH)2D3 in uremic 
models, conditional cardiac-specific VDR 
KO models, and models testing acute non-
genomic versus less acute genomic effects, 
will better delineate the precise mecha-
nisms of action and their relevance to 
patients with and without renal disease.
Patients with renal failure demon-
strate profound 25(OH)D3 deficiency, 
which has been recently associated with 
subsequent adverse cardiovascular out-
comes in patients with17 and without18 
overt kidney disease. In addition, as renal 
failure progresses, renal 1α-hydroxylase 
activity is suppressed; hence circulating 
levels of the active hormone 1,25(OH)2D3 
are also markedly lowered.17 While 
patients with kidney disease may have 
VDR polymorphisms that lead to altered 
ligand binding or altered post-binding 
signaling, the 1α-hydroxylase KO model 
provides mechanistic insights that link 
1,25(OH)2D3 deficiency — which is quite 
prevalent in patients with renal failure 
— with the virtually ubiquitous cardiac 
structural and functional alterations 
present in this population.
In vivo effects of 1,25(OH)2D3 on the 
heart appear to be independent of serum 
calcium and phosphorus levels, which is 
consistent with our own human obser-
vational studies suggesting that therapy 
with 1,25(OH)2D3 or its analogues is 
associated with a reduction in cardio-
vascular-related mortality independ-
ent of serum calcium and phosphorus 
levels.19,20 Human correlations exist, as 
children with rickets with cardiomyopa-
thy and cardiac hypertrophy markedly 
improve after therapy with vitamin D;21 
however, detailed studies in patients with 
renal disease are currently lacking. There-
fore, as fundamental efforts to define the 
mechanisms linking vitamin D sterols to 
cardiovascular benefits forge ahead, the 
existing data support the need to pro-
ceed with human studies testing whether 
various formulations of vitamin D have a 
cardioprotective effect, and whether they 
are safe to administer for this indication. 
The VDR KO, Dahl salt-sensitive, and 
1α-hydroxylase KO models of altered 
vitamin D metabolism, combined with 
suggestive observational studies, have 
now converged — as they ideally should 
— into prospective clinical studies 
(for example, the PRIMO and PRIMO 
II studies (ClinicalTrials.gov studies 
NCT0049714622 and NCT0061690223) 
that will test whether the cardiac effects 
of vitamin D sterols successfully translate 
from exquisite in vivo models to actually 
change patient outcomes.
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Figure 1 | M-mode echo in the Dahl salt-sensitive rat at 12 weeks. Representative M-mode 
echocardiograms at 12 weeks in animals treated with high salt plus vehicle or high salt plus 
activated vitamin D analogue. Dotted line represents end-diastolic diameter (D), and solid 
line represents end-systolic diameter (S). Animals treated with activated vitamin D analogue 
demonstrated higher fractional shortening and lower posterior wall thickness than vehicle-treated 
animals. (Adapted from ref. 16.)
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Beyond nutrition: neuropeptide 
signaling and muscle mass 
maintenance in chronic kidney 
disease
Tiffany K. Roberts1,2 and James L. Bailey1
Muscle wasting is a hallmark of uremic cachexia and has frequently 
been attributed to malnutrition that manifests as anorexia in chronic 
kidney disease. However, recent evidence indicates that proteolytic 
mechanisms are responsible for atrophy. Cheung and colleagues have 
reexamined the links between loss of lean body mass and nutrition. 
They demonstrate that neuropeptide signaling pathways, which 
regulate appetite and energy expenditure, also affect expression of key 
proteins involved in muscle mass maintenance.
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Patients with chronic kidney disease 
(CKD) suffer from cachexia, which is char-
acterized by muscle wasting, loss of pro-
tein stores, a low serum albumin, anorexia, 
and increased energy expenditures. This 
maladaptive response is further exacer-
bated by an inability to effectively utilize 
dietary nutrients. As a consequence, mor-
tality is substantially increased, and treat-
ment strategies to combat this response 
have been only partially successful. A 
study by Cheung et al.1 (this issue) pro-
vides some insight into how these central 
features of cachexia may be intertwined.
Elevated circulating levels of cytokines 
are frequently observed in uremic 
cachexia. Recent evidence indicates 
that cytokines can modify the release 
and/or function of neurotransmitters, 
thereby altering appetite. Leptin, which 
is secreted by adipocytes, is a member 
of the interleukin-6 family of cytokines. 
It communicates with the hypothala-
mus to decrease appetite and results in 
decreased food intake and an increase 
in energy expenditure.2 In fact, admin-
istration of leptin induces anorexia in 
mice.3 The level of leptin is increased 
in the presence of overfeeding, insulin, 
glucocorticoids, and angiotensin II and 
is decreased with fasting, testosterone, 
thyroid, and cold exposure.4
Leptin acts to regulate appetite 
through the melanocortin signaling 
pathway (Figure 1). Cheung and col-
leagues have previously used both gene 
deletion and pharmacologic approaches 
